"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in this website by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 3 | 5 |
| 2012 | 4 | 2 | 6 |
| 2013 | 0 | 5 | 5 |
| 2014 | 5 | 4 | 9 |
| 2015 | 4 | 9 | 13 |
| 2016 | 7 | 7 | 14 |
| 2017 | 6 | 17 | 23 |
| 2018 | 7 | 17 | 24 |
| 2019 | 13 | 20 | 33 |
| 2020 | 16 | 29 | 45 |
| 2021 | 12 | 30 | 42 |
| 2022 | 5 | 44 | 49 |
| 2023 | 6 | 44 | 50 |
| 2024 | 14 | 24 | 38 |
| 2025 | 13 | 29 | 42 |
| 2026 | 5 | 19 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Spatial and single-cell dissection of medulloblastoma identifies developmental hierarchies and a prognostic PPIA-BSG tumor-immune axis. J Transl Med. 2026 Sep 15; 24(1).
-
Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma. Cell Rep Med. 2026 Sep 15; 7(9):103008.
-
ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis Through Symbiotic Adhesion and Reverse Migration. Cancer Res. 2026 08 14; 86(16):4007-4027.
-
Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer. Cell. 2026 Sep 17; 189(19):6170-6188.e9.
-
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors. J Immunother Cancer. 2026 Jun 24; 14(6).
-
Biomarker study of pembrolizumab in patients with advanced rare cancers. Cell Rep Med. 2026 Jun 16; 7(6):102827.
-
Understanding and Overcoming Osteosarcoma Heterogeneity. Biomolecules. 2026 Jun 15; 16(6).
-
Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axis. Nat Commun. 2026 Jun 02; 17(1).
-
Targeting tumor-associated macrophage-induced IGF1/PI3K/Zic1 axis triggers SHH medulloblastoma regression and chemosensitization. Neuro Oncol. 2026 Jun 01; 28(6):1556-1570.
-
Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med. 2026 Jul 10; 7(7):101149.